Portage Biotech

60 articles with Portage Biotech

• Portage Biotech Issues Letter To Shareholders

  1/15/2016

• Mr. James Mellon And Dr. Gregory Bailey ("Offerors") Announce Additional Shares In Portage Biotech

  12/15/2015

• Portage Biotech's Biohaven Announces Phase 1 Pharmacokinetic Study Meets Study Objectives And Supports Advancing BHV-0223 And Also Appoints A CEO

  11/20/2015

• Portage Biotech's Biohaven Completes Multiple Dose Phase Of Pharmacokinetic Trial With BHV-0223

  10/6/2015

• Portage Biotech's Biohaven Completes Single Dose Phase Of Pharmacokinetic Trial With BHV-0223

  9/22/2015

• Portage Biotech Issues Letter To Shareholders

  9/10/2015

• Portage Biotech's PPL Will Advance Its Lead Candidate PPL-003 To An IND For Dry Eye Disease And Uveitis

  8/31/2015

• Portage Biotech's Biohaven Doses First Human Subject In Phase 1 Trial With Lead Drug Candidate BHV-0223

  8/27/2015

• Portage Biotech's Biohaven's Lead Drug Candidate Clears FDA Investigational New Drug Application (IND) Review And Clinical Studies To Begin

  8/24/2015

• Portage Biotech's Biohaven Acquires Intellectual Property For Portfolio Of Prodrugs From ALS Biopharma LLC

  8/18/2015

• Portage Biotech Invests In Sentien Biotechnologies Inc.

  8/10/2015

• Portage Biotech's Biohaven Announces IND Filing For Bhv-0223 For Phase 1 Clinical Testing

  7/23/2015

• Portage Biotech Completes Non-Brokered Private Placement In Two Tranches For A Total Proceeds Of US$ 5,155,080

  6/25/2015

• Portage Biotech Announces Proposed Private Placement

  5/20/2015

• Portage Biotech's Biohaven To Begin Phase 1 Study In 3Q2015 And Readying For Phase 3 Study Start By 1Q2016

  4/22/2015

• Portage Biotech's CPP Platform Delivers A Peptide Cargo Across Blood Brain Barrier

  4/20/2015

• Portage Biotech To Present At Master Investor 2015 In London, UK

  4/16/2015

• Portage Biotech's Biohaven Announces Agreement With inVentiv Health

  4/1/2015

• Portage Biotech's Biohaven Enters Into Exclusive Formulation Agreement And Global License With Catalent Pharma Solutions For Lead Product

  3/24/2015

• Portage Biotech Announces Additional Consultants To Expedite Its PPL-003 Development Programs

  10/6/2014